Oxbryta Compensation Claim Status: Two Years After the Recall, Limitations Clocks Are the Real Story

There is no Oxbryta compensation fund for injured patients. The only classwide money on the table is a refund: on 17 September 2026, Pfizer Inc. and Global Blood Therapeutics, Inc. asked the Northern District of California to preliminarily approve a settlement paying up to $750,000 for out-of-pocket purchases of the withdrawn sickle cell drug, while every bodily injury and wrongful death claim is being resolved, if at all, one case at a time and on confidential terms.

That split matters more now than it did a month ago. On 25 September 2026 the withdrawal passed its second anniversary, and two years is the personal injury limitations period in California, Pennsylvania, Texas and Georgia, among many other states. For a patient or family who has not filed, an Oxbryta compensation claim is no longer a question of which settlement to join. It is a question of whether a claim remains timely at all under the law of the state where it would be brought, and what the record shows about when the injury was, or reasonably should have been, connected to the drug.

Why Pfizer withdrew Oxbryta on 25 September 2024

Oxbryta (voxelotor) received accelerated approval from the FDA in 2019 for sickle cell disease in adults and children 12 and older, and the indication was extended in 2021 to children aged 4 to 11. It was marketed by Global Blood Therapeutics, which Pfizer acquired in 2022.

On 25 September 2024 Pfizer voluntarily withdrew all lots from every market worldwide, stopped distribution, and discontinued all active clinical trials and expanded access programs. The FDA's alert the following day recorded the company's conclusion that "the benefit of Oxbryta does not outweigh the risks for the sickle cell patient population." The agency identified the signal: post-marketing clinical trials showed a higher rate of vaso-occlusive crises in patients taking Oxbryta than in those on placebo, along with more deaths in the Oxbryta group, and two real-world registry studies also showed a higher rate of vaso-occlusive crises. The FDA told clinicians to stop prescribing the drug and patients to discuss alternatives with their providers.

The trial behind the most-cited mortality figure was HOPE-KIDS 2, a study in children at elevated risk of stroke. European regulators, confirming the suspension in October 2025, reported eight deaths among children taking Oxbryta against two on placebo. The EMA's committee also noted that the results conflicted with the earlier pivotal trial on which authorization rested.

The final regulatory word came on 4 August 2026. In a letter to the sickle cell community, Pfizer said that after two years of analysis shared with the FDA, "there is not a viable path to make Oxbryta available again in the U.S." For litigation purposes, that letter closes an argument some defendants make about voluntary withdrawals: that the product was paused pending review rather than condemned. It also states, in the company's own words, that the decision rested on data indicating "more vaso-occlusive crises" and "fatalities" for those taking the drug.

Is there an Oxbryta compensation fund or settlement program?

No. Nothing in the public record establishes a claims program, settlement matrix or qualified settlement fund for people who allege that Oxbryta caused vaso-occlusive crises, strokes or deaths. The only classwide settlement is the economic-loss deal in Jolly v. Global Blood Therapeutics, Inc., No. 3:24-cv-09345 (N.D. Cal.), which reimburses purchase costs.

That absence is the single most important fact for anyone searching for "Oxbryta recall compensation." Lead-generation pages routinely publish projected payout ranges for injury claims; none of those figures traces to any filed settlement, and none is repeated here. The settlements that have occurred are individual, their amounts are undisclosed, and they are documented in court records only as releases, stipulated dismissals and status reports.

The three compensation tracks, compared

Oxbryta claims fall into three categories that differ in who qualifies, what is paid and how the claim is pursued.

Track	Example case	What it compensates	Status (as of 19 Oct 2026)	How a person participates
Economic loss (class)	Jolly v. Global Blood Therapeutics, No. 3:24-cv-09345 (N.D. Cal.)	Out-of-pocket purchase costs only	Unopposed motion for preliminary approval filed 17 Sep 2026; fund capped at $750,000	Class Notice and claim form after preliminary approval; no lawsuit needed
Personal injury	Allen v. Global Blood Therapeutics, No. 3:24-cv-07786 (N.D. Cal.); W.D. Pa. minor's case before Judge Cathy Bissoon	Medical expense, pain and suffering, lost earnings, possibly Punitive Damages	Allen dismissed by stipulation 22 May 2026; W.D. Pa. release executed (reported 23 Jun 2026)	Individual lawsuit within the state limitations period
Wrongful death	Ford v. Global Blood Therapeutics (N.D. Cal.)	Losses to survivors and the estate	Settled in principle Oct 2025; formal agreement still being finalized in Feb 2026	Lawsuit by estate representative or statutory beneficiaries

How much is the Oxbryta Pfizer settlement?

The only disclosed figure is the $750,000 ceiling in the Jolly class settlement, reported by Mealey's on 17 September 2026. Pfizer and Global Blood Therapeutics agreed to fund reimbursements "up to" that amount for certain out-of-pocket purchases. It is a capped fund, so the companies pay valid claims up to the ceiling, and it is unopposed, meaning the defendants joined the plaintiffs' request for approval.

No dollar amount has been disclosed for any personal injury or wrongful death resolution. Allen ended with a stipulation of dismissal without prejudice, each side bearing its own fees and costs, pursuant to a settlement agreement whose terms are not on the docket. The Western District of Pennsylvania status report said only that the plaintiffs had executed a release. The Ford status report of 6 February 2026 said the parties were finalizing a formal settlement agreement.

The Jolly deal was analyzed in detail in this publication's earlier report on the $750,000 Oxbryta class action settlement. The point for this article is narrower: the refund fund is not an injury fund, and accepting a refund under it would not, on the reported terms, be the vehicle for compensation for a vaso-occlusive crisis, stroke or death.

Who qualifies for Oxbryta recall compensation?

Under the class track, eligibility turns on having paid for the drug. A purchaser who paid out of pocket during the class period would be a member of the Settlement Class once a class is certified for settlement purposes, and would receive Class Notice explaining how to claim, object or opt out. A patient whose insurer or a manufacturer assistance program covered the full cost has no out-of-pocket loss to reimburse. The class definition, claim deadline and documentation requirements will be fixed by the court's preliminary approval order; none had been publicly reported as of 19 October 2026.

Under the injury and death tracks, there is no eligibility list because there is no program. A claim requires a lawsuit (or a pre-suit resolution) built on four elements: use of Oxbryta, a recognized injury, evidence that Oxbryta caused that injury in that patient, and a timely filing. The injuries plaintiffs have pleaded include increased frequency or severity of vaso-occlusive crises, stroke, intensive care admissions and death.

Have any Oxbryta injury lawsuits settled?

Yes, at least three, all confidentially. The chronology below is drawn from dockets and trade reporting.

Date	Development
25 Sep 2024	Pfizer withdraws Oxbryta worldwide; FDA alert follows on 26 Sep
7 Nov 2024	Allen v. Global Blood Therapeutics filed in N.D. Cal.
May 2025	Ford wrongful death complaint filed; N.D. Cal. relates Frazier, Jolly and Allen before one judge
Aug 2025	Ford case set for trial on 13 Sep 2027
Oct 2025	Parties in Ford announce a tentative settlement; EMA confirms EU suspension
6 Feb 2026	Ford joint status report: formal settlement agreement being finalized
Late May 2026	W.D. Pa. status report: settlement reached in minor's VOC case
22 May 2026	Allen dismissed by stipulation without prejudice under a settlement agreement
23 Jun 2026	HarrisMartin reports plaintiffs executed a release in the W.D. Pa. case
4 Aug 2026	Pfizer letter: no viable path to return Oxbryta to the US market
17 Sep 2026	Unopposed motion for preliminary approval of the $750,000 Jolly settlement
25 Sep 2026	Second anniversary of the withdrawal

The Western District of Pennsylvania case is notable on its facts. According to reporting on the complaint, the plaintiff was a 13-year-old boy, identified by initials, who had taken part in a 2021 Oxbryta study and alleged repeated, life-threatening vaso-occlusive crises requiring intensive care and opioid pain management. The case was before U.S. District Judge Cathy Bissoon. Its resolution is reported to be limited to that one case.

Reporting has described the manufacturers as working with plaintiffs' counsel toward a broader resolution, but no global settlement, inventory deal or settlement matrix has been filed or announced.

Is there an Oxbryta MDL?

No. The Judicial Panel on Multidistrict Litigation has not created an Oxbryta docket, and the federal cases in California proceed instead under an ordinary related-case order. In May 2025 the Northern District of California related Frazier, Jolly and Allen so that one judge, U.S. District Judge Trina L. Thompson, would handle them. Other injury cases sit in other districts, including the Western District of Pennsylvania, and in state courts.

The absence of Multidistrict Litigation (MDL) has practical consequences that cut in both directions. Without an MDL there is no Plaintiff Fact Sheet (PFS) regime, no Census Registry, no Common Benefit Fund assessment and no Bellwether Trial program that would generate verdict values. Each case is priced on its own facts, which is why settlements so far are bilateral and confidential. The patient population is small relative to typical drug mass torts, since Oxbryta was a specialty therapy for a rare disease, and the number of filed cases has been described in the dozens, not thousands. That scale makes an MDL unlikely and individual negotiation the norm.

Is there a deadline to file an Oxbryta lawsuit?

Yes. Every injury and death claim is subject to a Statute of Limitations set by state law, and some states also impose a Statute of Repose. The deadline usually runs from the date of injury, or under the Discovery Rule from the date the claimant knew or reasonably should have known that the injury was caused by the product. For many Oxbryta users, the public withdrawal on 25 September 2024 is a date a defendant will argue started the clock, since it was the moment the link between the drug and vaso-occlusive crises became public. That argument means two-year states may already be closed for claims based on injuries known at the time of the recall.

The table below shows general personal injury limitations periods in several states with Oxbryta litigation or large sickle cell populations. These are the general rules only; product liability, wrongful death, minors' claims and tolling each carry their own provisions.

State	General personal injury period	Statute	Two years from 25 Sep 2024
California	2 years	Cal. Code Civ. Proc. § 335.1	Passed 25 Sep 2026
Pennsylvania	2 years	42 Pa. C.S. § 5524	Passed 25 Sep 2026
Texas	2 years	Tex. Civ. Prac. & Rem. Code § 16.003	Passed 25 Sep 2026
Georgia	2 years	O.C.G.A. § 9-3-33	Passed 25 Sep 2026
Tennessee	1 year	Tenn. Code Ann. § 28-3-104	One-year period passed 25 Sep 2025
New York	3 years	N.Y. C.P.L.R. 214	Runs to 25 Sep 2027

Three features of limitations law tend to keep claims alive that appear stale on the calendar.

First, the Discovery Rule. In states that apply it to product cases, the period may begin later than the withdrawal if a reasonable person in the patient's position would not have connected a particular crisis, stroke or death to Oxbryta on 25 September 2024. Whether that argument works depends on the patient's records and on how the forum state's courts treat publicized recalls.

Second, minority tolling. Many states suspend the limitations period while the injured person is a minor. Oxbryta was approved for children as young as four, and several filed cases involve children. A child's claim may remain timely long after an adult's would have expired, though the parent's own claims for medical expenses may follow a different clock.

Third, wrongful death timing. Death claims usually run from the date of death rather than the date of the earlier injury. A patient who died after the withdrawal, or whose death was later connected to the drug, may have a separate and later deadline than a living patient injured at the same time.

A Tolling Agreement between a claimant and the defendants can also pause the clock, but only if it is signed before the period expires. None has been publicly reported for Oxbryta.

What records matter for an Oxbryta claim?

The documents that decide whether a claim is viable, and what it is worth, are the same ones defendants will request in discovery. They fall into five groups.

1. Proof of use. Pharmacy dispensing records, specialty pharmacy shipment logs, prescription history and, for trial participants, study enrollment and consent documents. Because Oxbryta was largely dispensed through specialty channels, those records usually exist even if the patient no longer has bottles.
2. Baseline disease history. Hospital and clinic records showing the frequency and severity of vaso-occlusive crises before the patient started Oxbryta. The core causation question in every case is whether the crises increased after initiation, and that requires a pre-treatment baseline.
3. Post-initiation events. Emergency department visits, admissions, intensive care stays, transfusion records, stroke imaging and pain management records after the patient started the drug, with dates.
4. Discontinuation. Records showing when and how the patient stopped, including any events in the period after abrupt discontinuation. Pfizer's letter to health care providers said complications from abrupt interruption could not be excluded.
5. Damages and estate documents. Medical bills, insurer explanation-of-benefits statements, any Medical Lien notices from Medicaid or Medicare, employment and earnings records, and, in death cases, the death certificate, autopsy report if any, and letters of administration.

The same pharmacy and payment records also establish eligibility for the class refund. A person with both a purchase-cost loss and an injury claim should expect the two to be handled separately.

How the injury cases are likely to be defended

The pleadings in the related federal cases preview the defense themes. Pfizer moved in March 2025 to dismiss the Jolly class complaint, arguing federal preemption, inadequate pleading, lack of support for Punitive Damages and lack of standing. Those arguments carry over to individual cases in modified form.

Preemption (Products) is the most significant. For a prescription drug, a Failure to Warn claim survives preemption only if the manufacturer could have strengthened its label without prior FDA approval. Plaintiffs will rely on the post-marketing trial and registry data the FDA itself cited, arguing that the safety signal emerged early enough for a label change. Defendants will point to the accelerated approval framework and the confirmatory-trial process as the regulatory mechanism for exactly that kind of data.

Specific Causation is the second. Sickle cell disease itself causes vaso-occlusive crises, strokes and early death. Each plaintiff must show that Oxbryta, rather than the underlying disease, caused or worsened the particular injury. That is why baseline records dominate the evidence and why the Learned Intermediary Doctrine, directing the warnings inquiry to the prescriber rather than the patient, will feature in most cases.

The third is General Causation. The FDA alert and the EMA findings report an imbalance in trial arms. The EMA's statement that the final registry analysis did not confirm an increase in crises, and its observation that the pivotal trial showed no difference, give defendants material for a Daubert Challenge to plaintiffs' experts. No court has yet ruled on causation expert testimony in an Oxbryta case.

What it means for claimants, families and counsel

For patients and families, the practical line is between a refund and compensation. The Jolly settlement, if approved, will return some purchase costs to people who paid out of pocket. It is not a substitute for an injury claim, and it will not be announced as one. Anyone considering an injury or death claim faces a calendar that, in two-year states, has already run for injuries known at the recall date, subject to the Discovery Rule, minority tolling and wrongful death timing.

For plaintiffs' firms, the docket offers no aggregate leverage. There is no MDL, no bellwether, no published verdict and no disclosed settlement value. Every resolution so far has been bilateral, confidential and, in Allen, structured as a dismissal without prejudice. Intake screening will turn on a documented increase in crises after initiation, and on the forum's limitations rules, more than on volume.

For defendants, the individual-settlement strategy has kept the inventory small and the values private, and the 4 August 2026 letter removes any uncertainty about the drug's future that might have complicated settlement planning. The limitations defense will grow stronger with each month that passes after the second anniversary.

For the court, the next public milestone is a ruling on preliminary approval of the Jolly settlement, which would set the claim deadline, the notice plan and the date of a final fairness hearing.

Frequently asked questions

Is there an Oxbryta compensation fund or settlement program?

No. The only classwide settlement is a refund of out-of-pocket purchase costs, capped at $750,000, in Jolly v. Global Blood Therapeutics in the Northern District of California. There is no fund, matrix or claims program for injuries or deaths.

How much is the Oxbryta Pfizer settlement?

The disclosed figure is up to $750,000 for purchase reimbursements, according to the unopposed motion filed on 17 September 2026. The individual injury and wrongful death settlements in Allen, the Western District of Pennsylvania case and the Ford case are confidential.

Who qualifies for Oxbryta recall compensation?

For the refund settlement, people who paid out of pocket for Oxbryta will qualify under the class definition the court approves. For injury compensation, a person must bring an individual claim showing Oxbryta use, an injury such as increased vaso-occlusive crises, stroke or death, causation, and a timely filing.

Is there an Oxbryta MDL?

No. The JPML has not created one. Related federal cases in California are assigned to U.S. District Judge Trina L. Thompson under a May 2025 related-case order, and other cases proceed separately in other federal and state courts.

Is there a deadline to file an Oxbryta lawsuit?

Yes. State limitations periods apply, commonly two years in states such as California, Pennsylvania, Texas and Georgia, and one year in Tennessee. The second anniversary of the 25 September 2024 withdrawal has passed, although the Discovery Rule, tolling for minors and wrongful death rules can extend specific deadlines.

Why was Oxbryta withdrawn from the market?

Pfizer withdrew it worldwide on 25 September 2024 because post-marketing trials and registry data showed more vaso-occlusive crises and more deaths in patients taking Oxbryta than in comparison groups. On 4 August 2026 Pfizer said there was no viable path to return it to the US market.